Abstract:Abstract Background Janus kinase inhibitors (JAKi) are new targeted synthetic disease-modifying antirheumatic drugs (DMARDs) licenced in the UK to treat rheumatoid and psoriatic arthritides. Unlike currently often prescribed biological DMARDs, they target a different part of the inflammatory pathway and are taken orally. The aim of this study was to explore what UK-based rheumatology clinicians and inflammatory arthritis (IA) patients think about the awareness, prescription and use of JAKi; how they compare with biologics; and how the COVID-19 pandemic has affected how JAKi are viewed and prescribed. Methods Rheumatology clinicians and IA patients completed online surveys and participated in interviews/focus groups between September 2021 and January 2022. Survey data were analysed descriptively, and interview/focus group data underwent an inductive thematic analysis. Results 66.6% of patients had at least some awareness of JAKi, 73.0% from their rheumatology team. Problems getting earlier access to these drugs were raised by some patients, with many being prescribed JAKi after multiple other therapies had failed. 91.5% of clinicians prescribed JAKi in keeping with their local guidelines, with 72.3% prescribing them frequently as a monotherapy. Some clinicians had lingering safety concerns over JAKi use. Despite experiencing side effects and knowing of possible long-term risks, patients felt overall the benefits of JAKi outweighed the risks. 39.3% of patients were ‘very satisfied’ on JAKi, compared with 25.0% on biologics. Patients on JAKi appreciated their short half-life when it comes to infections, and their convenience as an oral therapy. When JAKi were discontinued in patients, it was predominantly due to inefficacy and non-cardiovascular adverse events. The COVID-19 pandemic resulted in increased prescription of JAKi as an alternative to injections and infusions, primarily to avoid potentially exposing patients to the coronavirus. Some patients believed their JAKi may confer some protection against developing severe COVID-19. Conclusion JAKi are an effective treatment option for IA and are liked by patients. The COVID-19 pandemic appears to have impacted their prescription favourably. However, clinicians have safety concerns over JAKi use. Any decision to go on a JAKi should be informed and take into account individual patient risk factors, circumstances and preferences.

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

JAK inhibitor selectivity: new opportunities, better drugs?

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

JAK Inhibitors: Prospects in Connective Tissue Diseases

A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

[JAK inhibition in the treatment of inflammatory rheumatic diseases]

Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment

JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition

JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases

JANUS KINASE ENZYME (JAK) INHIBITORS AND RHEUMATOID ARTHRITIS: A REVIEW OF THE LITERATURE

Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

Advance in research of selective JAK inhibitors for treating rheumatoid arthritis